Posted by Michael Wonder on 12 Sep 2022
The SMC recommends use of Hansa Biopharma's Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients
12 September 2022 - The SMC decision follows the recent positive NICE recommendation for Idefirix in England, Wales and Northern Ireland, expanding access for eligible patients across the UK.
Hansa Biopharma today announce the recommendation by the SMC for its first in class treatment Idefirix in the desensitisation of highly sensitised adult patients prior to kidney transplant from a deceased donor.
